BioCentury
ARTICLE | Clinical News

Hextend electrolyte formulation: BTIM will start Phase III

August 26, 1996 7:00 AM UTC

BioTime Inc. (BTIM), Berkeley, Calif. Product: Hextend electrolyte formulation Use: Expand blood plasma volume in major surgery involving substantial blood loss Status: BTIM will start Phase III test...